- ISIN
- US6412881053
- CUSIP
- 641288105
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Apr 22, 2021
Highlights
- Market Cap
- $518.23M
- Enterprise Value
- $576.10M
- EPS (TTM)
- -$0.45
- Total Revenue (TTM)
- $99.53M
- Gross Profit (TTM)
- $77.93M
- EBITDA (TTM)
- -$15.39M
- Year Range
- $7.56 - $19.60
- Target Price
- $20.50
- ROA (TTM)
- -15.04%
- ROE (TTM)
- -102.92%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NPCE Performance Chart
NeuroPace, Inc. (NPCE) is down 0.5% since the beginning of the year. At $15 per share, NPCE is trading 21.6% below its 52-week high of $20. Investors who bought $1,000 worth of NPCE shares 5 years ago would now be looking at an investment worth $618.
Loading charts...
Returns By Period
NeuroPace, Inc. (NPCE) has returned -0.45% so far this year and 47.65% over the past 12 months.
NeuroPace, Inc.
- 1D
- -1.66%
- 1M
- -9.16%
- YTD
- -0.45%
- 6M
- -7.19%
- 1Y
- 47.65%
- 3Y*
- 50.82%
- 5Y*
- -9.17%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NPCE Monthly Returns History
Based on dividend-adjusted daily data since Apr 22, 2021, NPCE's average daily return is +0.10%, while the average monthly return is +3.70%. At this rate, an investment would double in approximately 1.6 years.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2023 with a return of +214.1%, while the worst month was May 2024 at -46.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, NPCE closed higher 47% of trading days. The best single day was Nov 5, 2025 with a return of +38.1%, while the worst single day was May 9, 2024 at -36.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.01% | -3.64% | -9.81% | 28.21% | -1.90% | -7.07% | -0.45% | ||||||
| 2025 | 22.97% | -5.89% | -5.10% | -4.88% | 13.09% | -15.73% | -23.61% | 7.52% | 12.68% | -3.59% | 64.59% | -5.62% | 37.98% |
| 2024 | 41.80% | 10.60% | -18.37% | -1.59% | -46.81% | 9.41% | 2.25% | 2.46% | -11.99% | -7.46% | 64.34% | 5.57% | 8.54% |
| 2023 | 214.09% | 9.62% | -9.55% | 7.76% | -11.00% | 0.90% | -7.57% | 126.27% | 3.62% | -30.63% | 33.19% | 14.68% | 591.95% |
| 2022 | -20.04% | -3.23% | 5.26% | -2.07% | -22.51% | -20.55% | 18.38% | -27.47% | -11.76% | -20.00% | -46.33% | -7.45% | -85.22% |
| 2021 | 3.91% | -5.09% | 3.75% | -10.47% | -0.28% | -25.38% | -4.35% | -34.04% | 0.80% | -56.65% |
Benchmark Metrics
NeuroPace, Inc. has an annualized alpha of 15.23%, beta of 0.95, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since April 22, 2021.
- This stock participated in 156.45% of S&P 500 Index downside but only 80.64% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.23%
- Beta
- 0.95
- R²
- 0.04
- Upside Capture
- 80.64%
- Downside Capture
- 156.45%
Return for Risk
Risk / Return Rank
NPCE ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NeuroPace, Inc. (NPCE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NPCE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.24 | ||
| Sortino ratioReturn per unit of downside risk | -1.01 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.37 | -0.16 |
| Calmar ratioReturn relative to maximum drawdown | 1.84 | 2.78 | -0.94 |
| Martin ratioReturn relative to average drawdown | 3.59 | 12.44 | -8.85 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NeuroPace, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NeuroPace, Inc. was 95.13%, occurring on Dec 28, 2022. The portfolio has not yet recovered.
The current NeuroPace, Inc. drawdown is 42.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -95.13%Dec 2022 | 1y 8mo | — | 5y 1moApr 2021 - now |
Drawdown Indicators
| NPCE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.13% | -56.78% | -38.35% |
Max Drawdown (1Y)Largest decline over 1 year | -25.99% | -9.10% | -16.89% |
Max Drawdown (3Y)Largest decline over 3 years | -66.29% | -18.90% | -47.39% |
Max Drawdown (5Y)Largest decline over 5 years | -94.85% | -25.43% | -69.42% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -42.00% | -1.80% | -40.20% |
Average DrawdownAverage peak-to-trough decline | -60.93% | -10.71% | -50.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.30% | 2.03% | +11.27% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NeuroPace, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NeuroPace, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NPCE relative to other companies in the Medical Devices industry. Currently, NPCE has a P/S ratio of 5.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NPCE in comparison with other companies in the Medical Devices industry. Currently, NPCE has a P/B value of 35.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NPCE
Add NeuroPace, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NPCE